Article: Greer's Sublingual-Oral Immunotherapy Clinical Trials Support the Safety of Home Administration of Allergy Immunotherapy.

Results of Phase I Trials Announced at 2006 American Academy of Allergy Asthma and Immunology Annual Meeting

Phase III Studies Planned to Begin in Second Quarter 2006

MIAMI BEACH, Fla., March 6 /PRNewswire/ -- Greer reported results of Phase I safety and dosing trials for the sublingual-oral immunotherapy administration of its standardized dust mite, short ragweed, Timothy grass and cat hair extracts at the American Academy of Allergy Asthma and Immunology (AAAAI) annual meeting. Dr. Bob Esch, Vice President of Research and Development for Greer, presented the findings of Greer's clinical trials at the meeting, which was held March 3-7 at the Miami ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!